Lidocaine 50 mg/g Patch, 30 pouches
Other active recalls for Lidocaine (different manufacturers) — 1 · tap to view
Past resolved recalls for this product (1)
🆔 Identity & classification
Where does this data come from?
🏷️ RxNorm drug class
This medicine belongs to the Antiarrhythmic class.
Where does this data come from?
🏭 Manufacturer & labeler
Where does this data come from?
🩺 Clinical
Prescription lidocaine transdermal (Dermalid, Lidoderm, Ztildo) is used to relieve the pain of post-herpetic neuralgia (PHN; burning, stabbing pains, or aches that may last for months or years after a shingles infection). Nonprescription (over-the-counter) lidocaine (Absorbine Jr, Aspercreme, Lidocare, Salonpas, others) is also available to relieve minor pain in shoulders, arms, neck and legs in adults and children 12 years of age and older. Lidocaine is in a class of medications called local anesthetics. It works by stopping nerves from sending pain signals.
Read the full MedlinePlus article ↗- It's best to avoid using two lidocaine products at the same time unless your doctor says it's okay. When you use multiple products containing a local anesthetic, the total amount a...
- Can I use a lidocaine patch and a lidocaine cream at the same time?
- No — please don't do this. Heat significantly increases how much lidocaine is absorbed through your skin, which can push drug levels in your blood higher than they should be. Stick...
- Can I put a heating pad on the area where I applied a lidocaine patch?
Patient education
Supplement & herbal interactions
Some supplements/herbs that may interact with Lidocaine — tap one for details:
Where does this data come from?
Ask a licensed pharmacist directly — free, answered by our team.
🧪 Inactive Ingredients / Excipients
Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.
💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.
-
UNII K679OBS311
Carboxymethylcellulose sodium is a plant-derived thickening agent made from cellulose. In medicines, it acts as a binder to hold ingredients together, a disintegrant to help the tablet break apart, or a thickener in liquids.
-
UNII DO250MG0W6
A mineral compound containing aluminum that acts as an antacid and buffering agent. It helps neutralize stomach acid and is used as a pH buffer to stabilize the medicine's formulation.
-
UNII 7FLD91C86K
Edetate disodium is a chemical compound that binds and removes certain metal ions. In medicines, it acts as a preservative and stabilizer by preventing metals like calcium from interfering with the product's shelf life and consistency.
-
UNII 2G86QN327L
Gelatin is a protein derived from animal collagen, commonly used in medicines as a gelling agent and capsule material. It helps create soft or hard capsule shells that hold and release medication, and can also thicken liquid formulations.
-
UNII PDC6A3C0OX
Glycerin is a clear, thick liquid derived from plant oils or fats. It acts as a humectant to retain moisture, a sweetener, and a solvent in medications.
-
UNII 24H4NWX5CO
Kaolin is a naturally occurring clay mineral. It's used in tablets and capsules as a filler and absorbent to add bulk, improve texture, and help bind ingredients together.
-
UNII A2I8C7HI9T
Methylparaben is a preservative derived from benzoic acid that prevents growth of bacteria, fungi, and mold in medicines. It extends the product's shelf life and maintains safety during storage.
-
UNII 73861X4K5F
A synthetic polymer used as a binder and thickening agent in tablets and capsules. It helps hold ingredients together and can modify how quickly the medicine dissolves and is absorbed in your body.
-
UNII 532B59J990
Polyvinyl alcohol is a synthetic polymer made from plant-derived materials. It's used as a binder to hold ingredients together, a film-former in coatings, and a thickener in liquid formulations.
-
UNII 6DC9Q167V3
Propylene glycol is a clear liquid derived from petroleum or vegetable sources. It acts as a solvent, humectant, and preservative in medicines, helping dissolve active ingredients and maintain product stability.
-
UNII Z8IX2SC1OH
Propylparaben is a chemical preservative used to prevent bacterial and fungal growth in medicines and personal care products. It helps extend shelf life and maintain product safety during storage.
-
UNII 285CYO341L
Sodium polyacrylate is a synthetic polymer that absorbs and holds water. In medicines, it acts as a disintegrant, helping tablets break apart quickly in the stomach, and as a binder, holding tablet ingredients together.
-
UNII 506T60A25R
Sorbitol is a natural sugar alcohol derived from glucose. It serves as a sweetener, humectant, and bulking agent in medications to improve taste and help maintain moisture in the product.
-
UNII W4888I119H
Tartaric acid is a natural organic acid found in grapes and tamarinds. In medicines, it works as a buffer to control acidity, an antioxidant to prevent spoilage, and sometimes a flavoring or binding agent.
-
UNII 8W8T17847W
A nitrogen-containing chemical compound used in pharmaceuticals as a humectant to retain moisture, and sometimes as a keratolytic agent in topical formulations to help soften and remove dead skin cells.
-
UNII 059QF0KO0R
Water is a liquid solvent that dissolves and mixes ingredients together in liquid medicines, syrups, and injections. It helps distribute the active drug evenly throughout the product.
16 inactive ingredients listed in the exact product block matched to this NDC.
Where does this data come from?
ingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.Inactive ingredient FAQ
Are inactive ingredients the same for every manufacturer?
Why might an inactive ingredient be missing?
Can inactive ingredients matter?
💲 Pricing
A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.
| Price system | Per ea | Per package |
|---|---|---|
| Retail pharmacies payNADAC · weekly | $2.031 | $60.93 / 30 pouches |
| Medicaid paysCMS SDUD · 12 mo | $2.27 | $67.95 / 30 pouches |
| Medicare drug plans payPart D · Q2 2026 | $2.72 | $81.65 / 30 pouches |
Where does this data come from?
🔁 Therapeutic equivalents
| Product | Labeler | Pack | NADAC/unit | TE | Status | Price vs. this |
|---|---|---|---|---|---|---|
| Lidocaine 5% 50 mg/g 82347-0505-05 | YARAL | 30 patches | $1.915 | AB | FDA listed | save 6% |
| Lidocaine 50 mg/g 00591-2679-30 | Actavis | 30 pouches | $2.031 | AB | Availability likely | — |
| Lidocaine 50 mg/gthis 00591-3525-30 | Actavis | 30 pouches | $2.031 | AB | Availability likely | — |
| Lidocaine 50 mg/g 00603-1880-16 | Par | 30 pouches | $2.031 | AB | Availability likely | — |
| Lidocan IV 50 mg/g 59088-0910-54 | PURETEK | 30 pouches | $2.031 | AB | Availability likely | — |
| Lidocaine 700 mg 65162-0791-08 | Amneal | 30 patches | $2.031 | AB | Availability likely | — |
| Tridacaine XL 50 mg/g 73352-0845-30 | Trifluent | 30 packets | $2.031 | AB | Availability likely | — |
| Lidocaine 50 mg/g 59088-0396-54 | PureTek | 30 pouches | $2.031 | AB | Discontinued | — |
| Lidocaine 700 mg 42291-0477-30 | AvKARE | 30 patches | — | AB | FDA listed | — |
| Lidocaine 50 mg/g 42291-0495-30 | AVKARE | 30 pouches | — | AB | FDA listed | — |
| Lidocaine 50 mg/g 50090-1359-02 | A-S | 30 pouches | — | AB | FDA listed | — |
| Lidocaine 5% 50 mg/g 50090-7857-02 | A-S | 30 pouches | — | AB | FDA listed | — |
| Lidocaine 700 mg 50090-7894-02 | A-S | 30 patches | — | AB | FDA listed | — |
| Lidocaine 50 mg/g 51407-0827-30 | Golden | 30 pouches | — | AB | FDA listed | — |
| Lidocaine 50 mg/g 55154-2665-05 | Cardinal | 5 pouches | — | AB | FDA listed | — |
| Lidocaine 50 mg/g 55154-7228-05 | Cardinal | 5 patches | — | AB | FDA listed | — |
| Lidocaine 50 mg/g 55700-0142-30 | Quality | 30 pouches | — | AB | FDA listed | — |
| LidoPure Patch 59088-0712-00 | PureTek | 1 kit | — | — | FDA listed | — |
| Lidoxryl 59088-0722-00 | PureTek | 1 kit | — | — | FDA listed | — |
| Lidocan VII 50 mg/g 59088-0900-54 | PURETEK | 30 pouches | — | AB | FDA listed | — |
| Lidocan 700 mg 59088-0905-54 | PURETEK | 30 patches | — | AB | FDA listed | — |
| Lidocan III 50 mg/g 59088-0907-54 | PURETEK | 30 patches | — | AB | FDA listed | — |
| Lidocan V 50 mg/g 59088-0909-54 | PURETEK | 30 pouches | — | AB | FDA listed | — |
| Lidocan VI 50 mg/g 59088-0911-54 | PURETEK | 30 pouches | — | AB | FDA listed | — |
| Lidocaine 5% 50 mg/g 60760-0657-05 | St. | 5 patches | — | AB | FDA listed | — |
| Lidocaine 50 mg/g 60760-0880-05 | St. | 5 pouches | — | AB | FDA listed | — |
| Lidocaine 50 mg/g 61919-0588-30 | DIRECT | 1 g | — | AB | FDA listed | — |
| Lidoderm 700 mg 61959-0001-30 | TPU | 30 patches | — | AB | FDA listed | — |
| Lidocaine 50 mg/g 63629-5094-01 | Bryant | 30 pouches | — | AB | FDA listed | — |
| Lidocaine 50 mg/g 63629-7059-01 | Bryant | 30 pouches | — | AB | FDA listed | — |
| Lidocaine 50 mg/g 63629-8755-01 | Bryant | 30 pouches | — | AB | FDA listed | — |
| Lidocaine 5% 700 mg 68071-3620-03 | NuCare | 30 patches | — | AB | FDA listed | — |
| Lidocaine 50 mg/g 68788-7159-03 | Preferred | 30 pouches | — | AB | FDA listed | — |
| Lidocaine 700 mg 68788-8344-03 | Preferred | 30 patches | — | AB | FDA listed | — |
| Lidocaine 50 mg 70518-0566-00 | REMEDYREPACK | 30 patches | — | AB | FDA listed | — |
| Lidocaine 5% 50 mg/g 70518-4487-00 | REMEDYREPACK | 30 pouches | — | AB | FDA listed | — |
| Lidocaine 50 mg/g 70518-4502-00 | REMEDYREPACK | 30 pouches | — | AB | FDA listed | — |
| Lidocaine 50 mg/g 71335-1934-01 | Bryant | 30 pouches | — | AB | FDA listed | — |
| Lidocaine 700 mg 71335-1971-01 | Bryant | 30 patches | — | AB | FDA listed | — |
| Lidocaine 700 mg 72162-2085-03 | Bryant | 30 patches | — | AB | FDA listed | — |
| Lidocaine Patch 700 mg 72189-0387-30 | Direct_Rx | 30 patches | — | AB | FDA listed | — |
| Tridacaine III 50 mg/g 73352-0835-15 | Trifluent | 15 packets | — | AB | FDA listed | — |
| Lidocaine 50 mg/g 76420-0037-30 | Asclemed | 30 pouches | — | AB | FDA listed | — |
| Lidocaine 50 mg/g 76420-0887-30 | Asclemed | 30 pouches | — | AB | FDA listed | — |
| Lidocaine 5% 50 mg/g 76420-0899-30 | Asclemed | 30 pouches | — | AB | FDA listed | — |
| Lidocaine 700 mg 80425-0325-01 | Advanced | 30 patches | — | AB | FDA listed | — |
| Lidocaine 50 mg/g 80425-0404-01 | Advanced | 30 pouches | — | AB | FDA listed | — |
| Lidocaine 5% Patch 700 mg 82461-0611-15 | Medcore | 15 patches | — | AB | FDA listed | — |
| Lidocaine 50 mg/g 85509-2880-03 | PHOENIX | 30 pouches | — | AB | FDA listed | — |
| Lidocaine 50 mg/g 85766-0169-30 | Sportpharm | 30 pouches | — | AB | FDA listed | — |
| Lidocaine 700 mg 85766-0170-30 | Sportpharm | 30 patches | — | AB | FDA listed | — |
| Lidox 5 Patch 50 mg/g 87234-0505-03 | Injecta | 30 pouches | — | AB | FDA listed | — |
| Lidocaine 50 mg/g 67877-0767-30 | Ascend | 30 pouches | — | AB | FDA listed | — |
Where does this data come from?
⏳ Availability & generic status
This product is an FDA-approved generic. Other versions of the same drug are listed under Therapeutic equivalents, least expensive first.
Where does this data come from?
🗺️ Medicaid utilization & spend
📊 Medicare Part D spend CMS · PART D · 2026 (Q1)
🔬 Reported adverse events (FAERS)
Top reported reactions
Age at onset
Reporter sex
Serious outcomes
Where does this data come from?
📦 Packaging — all sizes for this product
| Package NDC | Description | Marketing start | Status |
|---|---|---|---|
| 00591-3525-30 You're viewing this | 30 POUCH in 1 CARTON (0591-3525-30) / 1 g in 1 POUCH (0591-3525-11) | 2013-09-15 | Active |
📄 Full prescribing information FDA SPL
⏱️ Dosage and Administration ▾
DOSAGE AND ADMINISTRATION Apply lidocaine patch 5% to intact skin to cover the most painful area. Apply the prescribed number of patches (maximum of 3), only once for up to 12 hours within a 24 hour period. Patches may be cut into smaller sizes with scissors prior to removal of the release liner (See HANDLING AND DISPOSAL ).
Clothing may be worn over the area of application. Smaller areas of treatment are recommended in a debilitated patient, or a patient with impaired elimination. If irritation or a burning sensation occurs during application, remove the patch(es) and do not reapply until the irritation subsides.
When lidocaine patch 5% is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered. Lidocaine patch 5% may not stick if it gets wet. Avoid contact with water, such as bathing, swimming or showering.
⛔ Contraindications ▾
CONTRAINDICATIONS Lidocaine patch 5% is contraindicated in patients with a known history of sensitivity to local anesthetics of the amide type, or to any other component of the product.
⚠️ Warnings ▾
WARNINGS Risk of Methemoglobinemia Cases of methemoglobinemia have been reported in association with local anesthetic use. Although all patients are at risk for methemoglobinemia, patients with glucose-6-phosphate dehydrogenase deficiency, congenital or idiopathic methemoglobinemia, cardiac or pulmonary compromise, infants under 6 months of age, and concurrent exposure to oxidizing agents or their metabolites are more susceptible to developing clinical manifestations of the condition. If local anesthetics must be used in these patients, close monitoring for symptoms and signs of methemoglobinemia is recommended.
Signs of methemoglobinemia may occur immediately or may be delayed some hours after exposure, and are characterized by a cyanotic skin discoloration and/or abnormal coloration of the blood. Methemoglobin levels may continue to rise; therefore, immediate treatment is required to avert more serious central nervous system and cardiovascular adverse effects, including seizures, coma, arrhythmias, and death. Discontinue lidocaine and any other oxidizing agents.
Depending on the severity of the signs and symptoms, patients may respond to supportive care, i.e., oxygen therapy, hydration. A more severe clinical presentation may require treatment with methylene blue, exchange transfusion, or hyperbaric oxygen. Accidental Exposure in Children Even a used lidocaine patch contains a large amount of lidocaine (at least 665 mg).
The potential exists for a small child or a pet to suffer serious adverse effects from chewing or ingesting a new or used lidocaine patch, although the risk with this formulation has not been evaluated. It is important for patients to store and dispose of lidocaine patch 5% out of the reach of children, pets and others (See HANDLING AND DISPOSAL ). Excessive Dosing Excessive dosing by applying lidocaine patch 5% to larger areas or for longer than the recommended wearing time could result in increased absorption of lidocaine and high blood concentrations, leading to serious adverse effects (see ADVERSE REACTIONS , Systemic Reactions ).
Lidocaine toxicity could be expected at lidocaine blood concentrations above 5 mcg/mL. The blood concentration of lidocaine is determined by the rate of systemic absorption and elimination. Longer duration of application, application of more than the recommended number of patches, smaller patients, or impaired elimination may all contribute to increasing the blood concentration of lidocaine.
With recommended dosing of lidocaine patch 5%, the average peak blood concentration is about 0.13 mcg/mL, but concentrations higher than 0.25 mcg/mL have been observed in some individuals.
🤒 Adverse Reactions ▾
ADVERSE REACTIONS Application Site Reactions During or immediately after treatment with lidocaine patch 5%, the skin at the site of application may develop blisters, bruising, burning sensation, depigmentation, dermatitis, discoloration, edema, erythema, exfoliation, irritation, papules, petechia, pruritus, vesicles, or may be the locus of abnormal sensation. These reactions are generally mild and transient, resolving spontaneously within a few minutes to hours. Allergic Reactions Allergic and anaphylactoid reactions associated with lidocaine, although rare, can occur.
They are characterized by angioedema, bronchospasm, dermatitis, dyspnea, hypersensitivity, laryngospasm, pruritus, shock, and urticaria. If they occur, they should be managed by conventional means. The detection of sensitivity by skin testing is of doubtful value.
Other Adverse Events Due to the nature and limitation of spontaneous reports in postmarketing surveillance, causality has not been established for additional reported adverse events including: Asthenia, confusion, disorientation, dizziness, headache, hyperesthesia, hypoesthesia, lightheadedness, metallic taste, nausea, nervousness, pain exacerbated, paresthesia, somnolence, taste alteration, vomiting, visual disturbances such as blurred vision, flushing, tinnitus, and tremor. Systemic (Dose-Related) Reactions Systemic adverse reactions following appropriate use of lidocaine patch 5% are unlikely, due to the small dose absorbed (see CLINICAL PHARMACOLOGY , Pharmacokinetics ).
Systemic adverse effects of lidocaine are similar in nature to those observed with other amide local anesthetic agents, including CNS excitation and/or depression (light-headedness, nervousness, apprehension, euphoria, confusion, dizziness, drowsiness, tinnitus, blurred or double vision, vomiting, sensations of heat, cold or numbness, twitching, tremors, convulsions, unconsciousness, respiratory depression and arrest). Excitatory CNS reactions may be brief or not occur at all, in which case the first manifestation may be drowsiness merging into unconsciousness.
Cardiovascular manifestations may include bradycardia, hypotension and cardiovascular collapse leading to arrest. To report SUSPECTED ADVERSE EVENTS, contact Teva at 1-888-838-2872 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch for voluntary reporting of adverse reactions.
🔄 Drug Interactions ▾
Drug Interactions Antiarrhythmic Drugs: Lidocaine patch 5% should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When lidocaine patch 5% is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered. Drugs That May Cause Methemoglobinemia When Used with Lidocaine Patch 5% Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia: Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfasalazine
🤰 Pregnancy ▾
Pregnancy Teratogenic Effects: Pregnancy Category B. Lidocaine patch 5% has not been studied in pregnancy. Reproduction studies with lidocaine have been performed in rats at doses up to 30 mg/kg subcutaneously and have revealed no evidence of harm to the fetus due to lidocaine.
There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, lidocaine patch 5% should be used during pregnancy only if clearly needed.
🧒 Pediatric Use ▾
Pediatric Use Safety and effectiveness in pediatric patients have not been established.
🆘 Overdosage ▾
OVERDOSAGE Lidocaine overdose from cutaneous absorption is rare, but could occur. If there is any suspicion of lidocaine overdose (see ADVERSE REACTIONS , Systemic Reactions ), drug blood concentration should be checked. The management of overdose includes close monitoring, supportive care, and symptomatic treatment.
Dialysis is of negligible value in the treatment of acute overdose with lidocaine. In the absence of massive topical overdose or oral ingestion, evaluation of symptoms of toxicity should include consideration of other etiologies for the clinical effects, or overdosage from other sources of lidocaine or other local anesthetics. The oral LD 50 of lidocaine HCl is 459 (346 to 773) mg/kg (as the salt) in non-fasted female rats and 214 (159 to 324) mg/kg (as the salt) in fasted female rats, which are equivalent to roughly 4000 mg and 2000 mg, respectively, in a 60 to 70 kg man based on the equivalent surface area dosage conversion factors between species.
🧬 Clinical Pharmacology ▾
CLINICAL PHARMACOLOGY Pharmacodynamics Lidocaine is an amide-type local anesthetic agent and is suggested to stabilize neuronal membranes by inhibiting the ionic fluxes required for the initiation and conduction of impulses. The penetration of lidocaine into intact skin after application of lidocaine patch is sufficient to produce an analgesic effect, but less than the amount necessary to produce a complete sensory block. Pharmacokinetics Absorption: The amount of lidocaine systemically absorbed from lidocaine patch is directly related to both the duration of application and the surface area over which it is applied.
In a pharmacokinetic study, three lidocaine patches were applied over an area of 420 cm 2 of intact skin on the back of normal volunteers for 12 hours. Blood samples were withdrawn for determination of lidocaine concentration during the application and for 12 hours after removal of patches. The results are summarized in Table 1.
Table 1 Absorption of lidocaine from Lidocaine Patch Normal volunteers (n= 15, 12-hour wearing time) Lidocaine Patch Application Site Area (cm 2 ) Dose Absorbed (mg) C max (mcg/mL) T max (hr) 3 patches (2100 mg) Back 420 64 ± 32 0.13 ± 0.06 11 hr When lidocaine patch is used according to the recommended dosing instructions, only 3 ± 2% of the dose applied is expected to be absorbed. At least 95% (665 mg) of lidocaine will remain in a used patch. Mean peak blood concentration of lidocaine is about 0.13 mcg/mL (about 1/10 of the therapeutic concentration required to treat cardiac arrhythmias).
Repeated application of three patches simultaneously for 12 hours (recommended maximum daily dose), once per day for three days, indicated that the lidocaine concentration does not increase with daily use. The mean plasma pharmacokinetic profile for the 15 healthy volunteers is shown in Figure 1. Figure 1 Mean lidocaine blood concentrations after three consecutive daily applications of three lidocaine patches simultaneously for 12 hours per day in healthy volunteers (n = 15).
1 Distribution: When lidocaine is administered intravenously to healthy volunteers, the volume of distribution is 0.7 to
2.7L/kg (mean 1.5 ±
0.6SD, n=15). At concentrations produced by application of lidocaine patch, lidocaine is approximately 70% bound to plasma proteins, primarily alpha-1-acid glycoprotein. At much higher plasma concentrations (1 to 4 mcg/mL of free base), the plasma protein binding of lidocaine is concentration dependent.
Lidocaine crosses the placental and blood brain barriers, presumably by passive diffusion. Metabolism: It is not known if lidocaine is metabolized in the skin. Lidocaine is metabolized rapidly by the liver to a number of metabolites, including monoethylglycinexylidide (MEGX) and glycinexylidide (GX), both of which have pharmacologic activity similar to, but less potent than that of lidocaine.
A minor metabolite, 2, 6-xylidine, has unknown pharmacologic activity but is carcinogenic in rats. The blood concentration of this metabolite is negligible following application of lidocaine patch 5%. Following intravenous administration, MEGX and GX concentrations in serum range from 11 to 36% and from 5 to 11% of lidocaine concentrations, respectively.
Excretion: Lidocaine and its metabolites are excreted by the kidneys. Less than 10% of lidocaine is excreted unchanged. The half-life of lidocaine elimination from the plasma following IV administration is 81 to 149 minutes (mean 107 ± 22 SD, n = 15).
The systemic clearance is 0.33 to
0.90L/min (mean 0.64 ±
0.18SD, n = 15).
📦 How Supplied / Storage and Handling ▾
HOW SUPPLIED Lidocaine patch 5% is available as the following: Carton of 30 patches, packaged into individual child-resistant envelopes. NDC 0591-3525-30 Store at 20 o to 25 o C (68 o to 77 o F) [See USP Controlled Room Temperature]. For more information, call Teva at 1-888-838-2872. Manufactured For: Teva Pharmaceuticals Parsippany, NJ 07054 Rev. B 4/2022
📋 Description ▾
DESCRIPTION Lidocaine patch 5% is comprised of an adhesive material containing 5% lidocaine, USP, which is applied to a white non-woven polyethylene terephthalate (PET) material backing and covered with a transparent PET release liner. The release liner is removed prior to application to the skin. The size of the patch is 10 cm x 14 cm.
Lidocaine, USP is chemically designated as acetamide, 2-(diethylamino)-N-(2,6-dimethylphenyl), has an octanol:water partition ratio of 43 at pH 7.4, and has the following structure: Each adhesive patch contains 700 mg of lidocaine, USP (50 mg per gram adhesive) in an aqueous base. It also contains the following inactive ingredients: glycerin, D-sorbitol, propylene glycol, polyvinyl alcohol, urea, sodium polyacrylate, carboxymethylcellulose sodium, gelatin, polyacrylic acid, kaolin, tartaric acid, dihydroxyaluminum aminoacetate, methylparaben, propylparaben, and edetate disodium.
1